Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Gossamer Bio, Inc.GOSS · Entity 6928 | Director | September 23, 2026 | September 25, 2026 |
| IMMUNIC, INC.VTL · Entity 6306 | Director · Chief Executive Officer | January 11, 2019 | January 15, 2019 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | EVP & COO | December 11, 2017 | December 13, 2017 |
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Director | June 22, 2023 | June 30, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Gossamer Bio, Inc.
Report date September 23, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.99 · Expires 2036-09-22 | Direct | 10,000 |
Reported balance
After 2026-09-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-23 · Grant · Acquired 10,000 · Balance 10,000 F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
IMMUNIC, INC.
Report date January 11, 2019 · Filed January 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.30 · Expires 2028-01-02 | Direct | 0 |
Reported balance
After 2019-01-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-11 · Disposition to issuer · Disposed 1,588,832 · Balance 0 F2: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. F1: Twenty five (25%) of the shares of common stock subject to the option vested on January 3, 2019, and thereafter, one forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly, such that all of the shares of common stock subject to the option are vested by January 3, 2022, subject to the reporting person's continuing to be a Service Provider (as defined in the Amended & Restated 2017 Inducement Equity Incentive Plan (the "Plan)) through each vesting date; provided, that, the unvested portion of the option, if any, that would vest during the 12-month period following his termination date had he remained employed by the Issuer through such date shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,854,376 |
Reported balance
After 2019-01-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-11 · Grant · Acquired 1,854,376 · Balance 1,854,376 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Vital Therapies, Inc. Common Stock. F4: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), twenty five percent (25%) of the RSUs vest annually after the vesting commencement date of January 11, 2019. One hundred percent (100%) of the unvested portion of the RSUs, if any, shall vest in the event of a Termination without Cause or Resignation for Good Reason (each as defined in the reporting person's Change of Control and Severance Agreement). |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty five (25%) of the shares of common stock subject to the option vested on January 3, 2019, and thereafter, one forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly, such that all of the shares of common stock subject to the option are vested by January 3, 2022, subject to the reporting person's continuing to be a Service Provider (as defined in the Amended & Restated 2017 Inducement Equity Incentive Plan (the "Plan)) through each vesting date; provided, that, the unvested portion of the option, if any, that would vest during the 12-month period following his termination date had he remained employed by the Issuer through such date shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).
F2: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation.
F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Vital Therapies, Inc. Common Stock.
F4: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), twenty five percent (25%) of the RSUs vest annually after the vesting commencement date of January 11, 2019. One hundred percent (100%) of the unvested portion of the RSUs, if any, shall vest in the event of a Termination without Cause or Resignation for Good Reason (each as defined in the reporting person's Change of Control and Severance Agreement).
Jazz Pharmaceuticals plc
Report date December 11, 2017 · Filed December 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 96,263 |
Reported balance
After 2017-12-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-12-11 · Exercise / conversion · Acquired 44,200 · Balance 96,263 F1: Includes 78 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2017. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 101,130 |
Reported balance
After 2017-12-11 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2017-12-11 · Exercise / conversion · Acquired 4,867 · Balance 101,130 |
| Ordinary SharesSEC Table I · non-derivative | Direct | 102,821 |
Reported balance
After 2017-12-11 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2017-12-11 · Exercise / conversion · Acquired 1,691 · Balance 102,821 |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.23 · Expires 2020-08-24 | Direct | 0 |
Reported balance
After 2017-12-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-12-11 · Exercise / conversion · Disposed 44,200 · Balance 0 F2: This incentive stock option is part of an option award granted on August 25, 2010. The ordinary shares subject to the option award vested over 4 years from the vesting commencement date of July 21, 2010, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of July 21, 2014. |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.83 · Expires 2022-08-08 | Direct | 0 |
Reported balance
After 2017-12-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-12-11 · Exercise / conversion · Disposed 4,867 · Balance 0 F3: This incentive stock option is part of an option award granted on August 9, 2012. The ordinary shares subject to the option award vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016. |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.13 · Expires 2023-03-04 | Direct | 0 |
Reported balance
After 2017-12-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-12-11 · Exercise / conversion · Disposed 1,691 · Balance 0 F4: This incentive stock option is part of an option award granted on March 5, 2013. The ordinary shares subject to the option award vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of March 5, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 78 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2017.
F2: This incentive stock option is part of an option award granted on August 25, 2010. The ordinary shares subject to the option award vested over 4 years from the vesting commencement date of July 21, 2010, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of July 21, 2014.
F3: This incentive stock option is part of an option award granted on August 9, 2012. The ordinary shares subject to the option award vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016.
F4: This incentive stock option is part of an option award granted on March 5, 2013. The ordinary shares subject to the option award vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of March 5, 2017.
Spyre Therapeutics, Inc.
Report date June 22, 2023 · Filed June 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2033-06-22 | Direct | 1,950,000 |
Reported balance
After 2023-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-22 · Grant · Acquired 1,950,000 · Balance 1,950,000 F1: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder. F2: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder.
F2: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2026 Filed Sep 25, 2026 20:43 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $10.99 | $0.00 |
DisclosureSEC source: 0001628280-26-063601 · wk-form4_1790369018.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-09-22 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:29 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001512984-26-000001 · wk-form4_1780691368.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2036-06-03 F1 · shares: Award made pursuant to Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 25, 2025 Filed Jun 26, 2025 20:38 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001728117-25-000057 · wk-form4_1750970302.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2035-06-24 F1 · shares: Award made pursuant to Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 01:58 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantNon-qualified stock option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001728117-24-000065 · wk-form4_1717725481.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2034-06-05 F1 · shares: Award made pursuant to Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 22, 2023 Filed Jun 30, 2023 20:33 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantStock Option (right to buy) · Derivative | 1,950,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-23-040335 · doc4.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,950,000 Underlying: Common Stock · 1,950,000 shares Expires 2033-06-22 F1 · date: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 20:15 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001728117-23-000083 · wf-form4_168634170109729.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-06-07 F1 · shares: Award made pursuant to Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 09, 2022 Filed Jul 15, 2022 21:06 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001728117-22-000073 · wf-form4_165791919498991.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-08 F1 · kind: Award made pursuant to Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer'sstockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 07, 2022 Filed Jun 10, 2022 01:13 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 43,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-22-035684 · doc4.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2032-06-06 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 23:49 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $8.97 | $0.00 |
DisclosureSEC source: 0001728117-21-000058 · wf-form4_162336895818140.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2031-06-08 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 21:23 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001209191-21-039224 · doc4.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-06-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 8, 2021, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 20:57 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (right to buy) · Derivative | 23,500 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001209191-20-037640 · doc4.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2030-06-16 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:23 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 28,100 | $0.00 Strike: $8.89 | $0.00 |
DisclosureSEC source: 0001209191-20-035510 · doc4.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,100 Underlying: Common Stock · 28,100 shares Expires 2030-06-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 8, 2020 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 22:35 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (right to buy) · Derivative | 23,500 | $0.00 Strike: $19.54 | $0.00 |
DisclosureSEC source: 0001209191-19-036216 · doc4.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2029-06-09 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 07, 2019 Filed Jun 7, 2019 20:49 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 12,400 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001567619-19-013070 · doc1.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,400 Underlying: Common Stock · 12,400 shares Expires 2029-06-06 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2019 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| February 12, 2019 Filed Feb 12, 2019 22:40 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | PurchaseCommon Stock | 7,200 | $16.00 | $115,200.00 |
DisclosureSEC source: 0001209191-19-009452 · doc4.xml · nonDerivative · entry 1 Cox Russell J. · CIK 0001512984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,200 Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:50 UTC | IMMUNIC, INC. VTL · Entity 6306 | GrantRestricted Stock Units · Derivative | 1,854,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001280776-19-000018 · wf-form4_154752058722280.xml · derivative · entry 2 Cox Russell J. · CIK 0001512984 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,854,376 Underlying: Common Stock · 1,854,376 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Vital Therapies, Inc. Common Stock. F4 · derivative.exercise_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), twenty five percent (25%) of the RSUs vest annually after the vesting commencement date of January 11, 2019. One hundred percent (100%) of the unvested portion of the RSUs, if any, shall vest in the event of a Termination without Cause or Resignation for Good Reason (each as defined in the reporting person's Change of Control and Severance Agreement). F4 · derivative.expiration_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), twenty five percent (25%) of the RSUs vest annually after the vesting commencement date of January 11, 2019. One hundred percent (100%) of the unvested portion of the RSUs, if any, shall vest in the event of a Termination without Cause or Resignation for Good Reason (each as defined in the reporting person's Change of Control and Severance Agreement). Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:50 UTC | IMMUNIC, INC. VTL · Entity 6306 | Disposition to issuerStock Option (right to buy) · Derivative | 1,588,832 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001280776-19-000018 · wf-form4_154752058722280.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,588,832 shares Expires 2028-01-02 F2 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. F1 · derivative.exercise_date: Twenty five (25%) of the shares of common stock subject to the option vested on January 3, 2019, and thereafter, one forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly, such that all of the shares of common stock subject to the option are vested by January 3, 2022, subject to the reporting person's continuing to be a Service Provider (as defined in the Amended & Restated 2017 Inducement Equity Incentive Plan (the "Plan)) through each vesting date; provided, that, the unvested portion of the option, if any, that would vest during the 12-month period following his termination date had he remained employed by the Issuer through such date shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan). Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 22:43 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 18,400 | $0.00 Strike: $10.28 | $0.00 |
DisclosureSEC source: 0001140361-18-027927 · doc1.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,400 Underlying: Common Stock · 18,400 shares Expires 2028-06-06 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2018 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 02:04 UTC | IMMUNIC, INC. VTL · Entity 6306 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 1,588,832 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001280776-18-000004 · wf-form4_151511784041634.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,588,832 Underlying: Common Stock · 1,588,832 shares Expires 2028-01-02 F1 · derivative.exercise_date: Twenty five (25%) of the shares of common stock subject to the option shall vest one year from January 3, 2018, and thereafter, one forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly, such that all of the shares of common stock subject to the option are vested by January 3, 2022, subject to the reporting person's continuing to be a Service Provider (as defined in the Amended & Restated 2017 Inducement Equity Incentive Plan (the "Plan)) through each vesting date; provided, that, the unvested portion of the option, if any, that would vest during the 12-month period following his termination date had he remained employed by the Issuer through such date shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan). Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 22:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,691 | $0.00 Strike: $59.13 | $0.00 |
DisclosureSEC source: 0001628280-17-012316 · wf-form4_151320561424812.xml · derivative · entry 6 Cox Russell J. · CIK 0001512984 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,691 shares Expires 2023-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This incentive stock option is part of an option award granted on March 5, 2013. The ordinary shares subject to the option award vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of March 5, 2017. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 22:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 4,867 | $0.00 Strike: $46.83 | $0.00 |
DisclosureSEC source: 0001628280-17-012316 · wf-form4_151320561424812.xml · derivative · entry 5 Cox Russell J. · CIK 0001512984 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,867 shares Expires 2022-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This incentive stock option is part of an option award granted on August 9, 2012. The ordinary shares subject to the option award vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 22:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 44,200 | $0.00 Strike: $8.23 | $0.00 |
DisclosureSEC source: 0001628280-17-012316 · wf-form4_151320561424812.xml · derivative · entry 4 Cox Russell J. · CIK 0001512984 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 44,200 shares Expires 2020-08-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This incentive stock option is part of an option award granted on August 25, 2010. The ordinary shares subject to the option award vested over 4 years from the vesting commencement date of July 21, 2010, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of July 21, 2014. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 22:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 1,691 | $59.13 | $99,988.83 |
DisclosureSEC source: 0001628280-17-012316 · wf-form4_151320561424812.xml · nonDerivative · entry 3 Cox Russell J. · CIK 0001512984 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 22:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 4,867 | $46.83 | $227,921.61 |
DisclosureSEC source: 0001628280-17-012316 · wf-form4_151320561424812.xml · nonDerivative · entry 2 Cox Russell J. · CIK 0001512984 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 22:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 44,200 | $8.23 | $363,766.00 |
DisclosureSEC source: 0001628280-17-012316 · wf-form4_151320561424812.xml · nonDerivative · entry 1 Cox Russell J. · CIK 0001512984 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 78 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2017. Read SEC document |
| December 01, 2017 Filed Dec 6, 2017 02:00 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001140361-17-045121 · doc1.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-11-30 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on January 1, 2018 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 21:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 978 | $155.56 | $152,137.68 |
DisclosureSEC source: 0001512984-17-000005 · edgardoc.xml · nonDerivative · entry 1 Cox Russell J. · CIK 0001512984 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,985 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: Includes 168 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2017. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 22:32 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,793 | $132.81 | $238,128.33 |
DisclosureSEC source: 0001232524-17-000067 · edgardoc.xml · nonDerivative · entry 1 Cox Russell J. · CIK 0001512984 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,795 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 23:44 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 24,266 | $0.00 Strike: $136.18 | $0.00 |
DisclosureSEC source: 0001232524-17-000057 · edgardoc.xml · derivative · entry 3 Cox Russell J. · CIK 0001512984 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,266 Underlying: Ordinary Shares · 24,266 shares Expires 2027-03-01 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 23:44 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 734 | $0.00 Strike: $136.18 | $0.00 |
DisclosureSEC source: 0001232524-17-000057 · edgardoc.xml · derivative · entry 2 Cox Russell J. · CIK 0001512984 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 734 Underlying: Ordinary Shares · 734 shares Expires 2027-03-01 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 23:44 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-17-000057 · edgardoc.xml · nonDerivative · entry 1 Cox Russell J. · CIK 0001512984 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,588 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2017, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:01 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 2,507 | $136.97 | $343,383.79 |
DisclosureSEC source: 0001512984-17-000002 · edgardoc.xml · nonDerivative · entry 1 Cox Russell J. · CIK 0001512984 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,588 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| January 18, 2017 Filed Jan 19, 2017 23:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3,000 | $130.00 | $390,000.00 |
DisclosureSEC source: 0001232524-17-000004 · edgardoc.xml · nonDerivative · entry 2 Cox Russell J. · CIK 0001512984 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,095 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 18, 2017 Filed Jan 19, 2017 23:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,000 | $125.00 | $125,000.00 |
DisclosureSEC source: 0001232524-17-000004 · edgardoc.xml · nonDerivative · entry 1 Cox Russell J. · CIK 0001512984 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,095 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 57 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.